Please login to the form below

Not currently logged in
Email:
Password:

Alprolix

This page shows the latest Alprolix news and features for those working in and with pharma, biotech and healthcare.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as

Latest news

  • Novo Nordisk wins European approval for Refixia Novo Nordisk wins European approval for Refixia

    than standard factor IX products, meaning fewer injections are needed,. Consequently Novo is hoping the new product will help defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog

  • Novo Nordisk's long-acting haemophilia B drug cleared by FDA Novo Nordisk's long-acting haemophilia B drug cleared by FDA

    Novo Nordisk has claimed US approval for Rebinyn, its long-acting Factor IX for haemophilia B, setting up a marketing battle with Bioverativ's Alprolix and CSL Behring's Idelvion. ... company does not divulge sales results, it is expected to make a

  • Keytruda and Opdivo backed for new uses in Europe Keytruda and Opdivo backed for new uses in Europe

    defend its franchise from rival long-acting haemophilia B drug Alprolix (eftrenonacog alfa) from Biogen and Swedish Orphan Biovitrum which was approved in the EU last year.

  • Biogen's CEO Scangos to step down Biogen's CEO Scangos to step down

    Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs Eloctate and Alprolix, which

  • Biogen plans spin-out of haemophilia business Biogen plans spin-out of haemophilia business

    In the first quarter, sales of Alprolix were $75m, with Eloctate adding $108m to the pot. ... When Biogen brought Eloctate and Alprolix to market … they represented the first major treatment advances in nearly two decades for people living with

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

  • A rare opportunity A rare opportunity

    Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for haemophilia B in the region. “

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics